醫師介紹
Doctor Introduction
:::
個人介紹
陳涵栩 Harn-Shen Chen
醫療副院長
陳涵栩醫師為糖尿病及腦垂體的權威專家。研究方向聚焦於早期胰島素的治療，並參與多項腸泌素的國際臨床試驗。
過去於台北榮總創立腦垂體多專科團隊，成為全台灣第一個腦垂體卓越中心，肢端肥大症的臨床研究全台首屈一指，也曾擔任台北榮民總醫院第一屆甲狀腺癌多專科團隊的召集人。現擔任中國醫藥大學附設醫院醫療副院長，致力於內分泌疾病之診斷與治療，並積極參與學術研究與專業發展，提供以病人為中心之優質醫療服務。
學術論文
期刊論文
|
期刊論文／Journal Paper (作者群，論文題目，期刊名稱，出版年月，卷號(期別):頁次起迄) |
日期 | |
| 1 | 楊景涵(Jin-Han Yang)、葉雲凱(Yun-Kai Yeh)、陳涵栩(CHEN HARN-SHEN)*，Intensive Glycemic Control in Adults Aged 80 Years and Older: A Randomized Trial Evaluating Diabetes Complications and Competing Mortality，DIABETES RESEARCH AND CLINICAL PRACTICE，2026 Sep，239(): | 2026 . 09 |
| 2 | 吳崇暉(Tsung-Hui Wu)、郭錦松(Chin-Sung Kuo)、陳涵栩(CHEN HARN-SHEN)*，Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia，Journal of the Chinese Medical Association，2026 Jul，89(7):517-524 | 2026 . 07 |
| 3 | 黃君睿(Chun-Jui Huang)、楊舜節(Shun-Jie Yang)、鄭正平(Cheng-Pin Cheng)、陳涵栩(CHEN HARN-SHEN)*，Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real-world experience，DIABETIC MEDICINE，2026 Jul，43(7): | 2026 . 07 |
| 4 | 吳慈恩(Tzu-En Wu)、陳涵栩(CHEN HARN-SHEN)*，Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations，Journal of the Chinese Medical Association，2026 Jun，89(6):407-414 | 2026 . 06 |
| 5 | 陳俊維(Jun-Wei Chen)、游子恩(Frederick Tzu-En Yu)、陳信安(Hsin-An Chen)、黃資富(Tzu-Fu Huang)、陳涵栩(CHEN HARN-SHEN)*、吳慈恩(Tzu-En Wu)*，Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Evidence from a Global Real-World Cohort，DIABETES & METABOLISM，2026 Mar，52(2):101740 | 2026 . 03 |
| 6 | 蔣柏緯(Po-Wei Chiang)、陳涵栩(CHEN HARN-SHEN)*，Prevalence and Clinical Correlates of Pre-operative Glucose Homeostasis in Patients with Acromegaly，GROWTH HORMONE & IGF RESEARCH，2026 Feb，84(): | 2026 . 02 |
| 7 | 楊景涵(Jin-Han Yang)、王緯歆(Wei-Hsin Wang)、陳涵栩(CHEN HARN-SHEN)*，Evaluating pituitary tumor management: aligning with pituitary tumor centers of excellence criteria，Pituitary，2025 Aug，28(5):91 | 2025 . 08 |
| 8 | 蘇郁文(Yu-Wen Su)、許惠恒(Wayne Huey-Herng Sheu)、陳涵栩(CHEN HARN-SHEN)*，Application of machine learning algorithms to identify risk factors for depression in type 2 diabetes mellitus patients: A Taiwan diabetes registry study.，Journal of the Chinese Medical Association，2025 Jul，88(7):513-519 | 2025 . 07 |
| 9 | 歐陽瑩芸(Ying-Yun Ou-Yang)、陳涵栩(CHEN HARN-SHEN)*，Rapid HbA1c reduction may reduce diabetes-related complications in patients with severe hyperglycemia，Journal of Biomedical Research & Environmental Sciences，2024 Oct，5(10):1379-1378 | 2024 . 10 |
| 10 | 郭錦松(Chin-Sung Kuo)、陳涵栩(CHEN HARN-SHEN)*，β-cell function and long-term glycemic control in patients newly diagnosed with type 2 diabetes with moderate hyperglycemia after a 6-month course of basal insulin therapy，DIABETES RESEARCH AND CLINICAL PRACTICE，2024 Sep，215():111814. | 2024 . 09 |
| 11 | 鄭菀韻(Wan-Yin Cheng)、張立心(Li-Hsin Chang)、陳涵栩(CHEN HARN-SHEN)*，The Effect of Statin Treatment on Glucose Homeostasis in Prediabetic Individuals: a prospective, randomized, controlled trial，Journal of the Chinese Medical Association，2024 Jul，87(7):664-669 | 2024 . 07 |
開關
首頁
Facebook
Instagram
體系醫院
中國醫點通